Antiproliferation and apoptosis induction of paenol in HepG2 cells

World Journal of Gastroenterology

Volumn 13, Issue 2, 2007, Pages 250-256

  Xu, Shu Ping ^a   Sun, Guo Ping ^a   Shen, Yu Xian ^a   Wei, Wei ^a   Peng, Wan Ren ^a   Wang, Hua ^b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

5 fluororacil; Apoptosis; Cell cycle; Cisplatin; Doxorubicin; Hepatocellular carcinoma; Paeonol; Synergistic effect

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ACRIDINE ORANGE; CISPLATIN; DOXORUBICIN; FLUOROURACIL; PEONOL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG POTENTIATION; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; LIVER CELL CARCINOMA; MITOSIS INHIBITION; STATISTICAL SIGNIFICANCE;

EID: 33846906765     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i2.250     Document Type: Article

References (29)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156
2. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005; 19:3-23
3. Johnson PJ. Hepatocellular carcinoma: is current therapy really altering outcome? Gut 2002; 51: 459-462
4. Shu X McCulloch M, Xiao H, Broffman M, Gao J. Chinese herbal medicine and chemotherapy in the treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Integr Cancer Ther 2005; 4: 219-229
5. Riley CM, Ren TC. Simple method for the determination of paeonol in human and rabbit plasma by high-performance liquid chromatography using solid-phase extraction and ultraviolet detection. J Chromatogr 1989; 489: 432-437
6. Sun GP, Wang H, Shen YX, Xu SY. Inhibitory effects of paeonol on the proliferation on four tumor cell lines. Anhui Yiyao 2004; 8: 85-87
7. Sun GP, Shen YX, Zhang LL, Zhou AW, Wei W, Xu SY. Study on immunomodulation and antitumor activity of paeonol. in HepA tumor mice. Zhongguo Yaolixie Tongbao 2003; 19:160-162
8. Sun GP, Shen YX Zhang LL, Wang H, Wei W, Xu SY. Antitumor effect of paeonol in vitro and in vivo. Anhui Keji Xueyuan Xuebao 2002; 37: 183-185
9. Cao SS, Zhen YS. Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B. Cancer Chemother Pharmacol 1989; 24: 181-186
10. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 2006; 11: 790-800
11. Okada S, Okazaki N, Nose H, Shimada Y, Yoshimori M, Aoki K. A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology 1993; 50: 22-26
12. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988; 62: 479-483
13. Lin DY, Lin SM, Liaw YF. Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12: S319-S328
14. Leung TW, Patt YZ, Lau WY, Ho SK, Yu SC, Chan AT, Mok TS, Yeo W, Liew CT, Leung NW, Tang AM, Johnson PJ. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999; 5: 1676-1681
15. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A, Johnson PJ. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97: 1532-1538
16. Lee J, Park JO, Kim WS, Park SH, Park KW, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Joh J, Kim K, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Park K. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol 2004; 54: 385-390
17. Yin XY, Lu MD, Liang LJ, Lai JM, Li DM, Kuang M. Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma. World J Gastroenterol 2005; 11: 2526-2529
18. Mimura K, Baba S. Determination of paeonol metabolites in man by the use of stable isotopes. Chem Pharm Bull (Tokyo) 1981; 29: 2043-2050
19. Sun YC, Shen YX, Sun GP. Advances in the studies of major pharmacological activity of paeonol. Zhongchengyao Zazhi 2004; 26: 579-582
20. Jiang SP, Chen YX. Advances and application in the studies of the Pycnostelma paniculatum (Bunge) K.S. and paeonol. Zhongguo Zhongyao Zazhi 1994; 19: 311-314
21. Ji CY, Tan SY, Liu CQ. Inhibitory effect of paeonol on the proliferation of human colorectal cancer cell line HT-29 and its synergistic effect with chemotherapy agents. Zhongguo Zhongyao Zazhi 2005; 17 122-124
22. Liu CQ, Tan SY, Ji CY, Luo, HS, Yu JP. The effects of paeonol on inhibiting the proliferation of human colorectal cancer cell line HT-29 and its molecule mechanism. Zhongguo Yaolixie Tongbao 2005; 21: 1251-1254
23. Sun GP, Wang H, Shen YX, Zhai ZM, Wei W, Xu SY. Study on effects of paeonol in inhibiting growth of K562 and inducing its apoptosis. Zhongguo Yaolixie Tongbao 2004; 20: 550-552
24. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411: 342-348
25. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994; 73: 2013-2026
26. Petru. E, Sevin BU, Haas J, Ramos R, Perras J. A correlation of cell cycle perturbations with chemosensitivity in human ovarian cancer cells exposed to cytotoxic drugs in vitro. Gynecol Oncol 1995; 58: 48-57
27. Bergerat JP, Barlogie B, Gohde W, Johnston DA, Drewinko B. In vitro cytokinetic response of human colon cancer cells to cis-dichlorodiammineplatinum(II). Cancer Res 1979; 39: 4356-4363
28. Takahashi K, Ebihara K, Honda Y, Nishikawa K, Kita M, Oomura M, Shibasaki C. Antitumor activity of cis-dichlorodiammineplatinum(II) and its effect on cell cycle progression. Gan To Kagaku Ryoho 1982; 9: 624-631
29. Potter AJ, Rabinovitch PS. The cell cycle phases of DNA damage and repair initiated by topoisomerase II-targeting chemotherapeutic drugs. Mutat Res 2005; 572: 27-44